Search
Leukemia, MDS
URCC 19185
Multicenter Randomized Controlled Trial comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
ALLIANCE A212102 **AT MBMC ONLY** **As of 8/1/23 the following Healthy Control Cohorts are Open (all others are Closed as of 2/22/23): Non-White Male Participants Age 60 or More Without Cancer Diagnosis and Non-White Male Participants Under Age 60 Without Cancer Diagnosis** **Effective with the release of Update #02, enrollment to the thyroid, melanoma, and sarcoma cancer cohorts has been closed.**
Blinded Reference Set For Multicancer Early Detection Blood Tests
URCC 19075 **MBMC ONLY**
Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)
EA9213 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)
URCC-21038 ***Sites must enroll a Black patient and then be able to enroll a White patient within the following three months**
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
URCC 18007
Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue
EA9171 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
